Replies to post #35981 on Revive Therapeutics Ltd (RVVTF)

[rickstereo3333]

The unbridled ignorance is palpable.................



75% of the hospitalizations were in the Placebo group based on low dose for Bucillamine and 100% of the hospitalizations were from Placebo in the High dose Bucillamine trials.

data demonstrated that for patients with oxygen saturation <96% at baseline, Bucillamine had a 29.1% improvement over placebo in time to normal oxygen saturation (SpO2)"

Additional analyses of the Study data are ongoing, which could support certain strategic decisions on pursuing the development and commercialization of Bucillamine



Whether the latter analyses bears any fruit remains to be seen but do stop with this nonsensical diatribe.

While you may be able to CONvince some here, there are those who actually "read between the lines" and extract the not so obvious nuggets of info.